Sheila R Fortunato

Title: Sheila R. Fortunato: Innovator in Cancer Research

Introduction

Sheila R. Fortunato is a prominent inventor based in Hollis, NY (US), known for her significant contributions to cancer research. She has been instrumental in developing innovative solutions that target specific tumor antigens, which can lead to advancements in cancer treatment.

Latest Patents

Sheila holds one patent titled "Human monoclonal antibodies to cell surface antigens of melanoma." This invention provides a monoclonal antibody, produced by the hybridoma cell line designated GXM1, which specifically binds to a human class 1 tumor antigen. Additionally, it includes a human monoclonal antibody, produced by a hybridoma cell line designated HJM1, which specifically binds to each of the ganglioside antigens GD2, GD3, GM3, and GD1b. Furthermore, the invention offers a human monoclonal antibody, produced by a hybridoma cell line designated FCM1, which specifically binds to the ganglioside antigens GM3 and GD1a. Lastly, it provides a human monoclonal antibody, produced by a hybridoma cell line designated DSM1, which specifically binds to a human class 2 tumor protein antigen.

Career Highlights

Sheila is affiliated with the Sloan-Kettering Institute for Cancer Research, where she has dedicated her career to advancing cancer therapies. Her work has been pivotal in understanding the mechanisms of melanoma and developing targeted treatments.

Collaborations

Sheila has collaborated with notable colleagues in her field, including Hiroshi Yamaguchi and Koichi Furukawa. These partnerships have enhanced her research and contributed to the development of innovative cancer therapies.

Conclusion

Sheila R. Fortunato's work in developing monoclonal antibodies represents a significant advancement in cancer research. Her contributions continue to pave the way for new treatment options for melanoma and other cancers.